# US 2026/0083858 A1 · Antibody drug conjugate comprising nmt inhibitor and its use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083858 A1
- Document ID: US20260083858A1
- Status: Published application
- Kind: A1
- Application number: 19/109,326
- Filed: 2023-09-08
- Published: 2026-03-26
- Earliest claimed: 2022-09-09
- Assignees: MyricX Pharma Limited; Imperial College Innovations Limited
- Applicants: MyricX Pharma Limited; Imperial College Innovations Limited
- Inventors: Robin CARR; Roberto SOLARI; Edward William TATE; Andrew Simon BELL; Roger BONNERT
- Web page: https://patentgrep.com/patent/US20260083858A1

## CPC

- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6863: {the tumour determinant being from stomach or intestines cancer cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- C07K 16/2887: {against CD20}
- C07K 16/32: against translation products of oncogenes
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/30: from tumour cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, and related uses.

## Claims

### Claim at position 1

1-92. (canceled)

### Claim 93

An antibody drug conjugate (ADC) comprising a NMT inhibitor conjugated to an antibody via a linker, or a salt thereof.

### Claim 94 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the NMT inhibitor is a compound of formula (I):
wherein:
Y is selected from the group consisting of —CH—, —C(R2)—and —N—;
R1 is a group of formula —X-L-A;
X represents —O—;
L represents —(CH2)m—;
m is 1, 2 or 3;
A is a 6-10-membered aromatic carbocycle or a 5-10-membered aromatic heterocycle, said aromatic carbocycle or heterocycle being optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of —F, —Cl, —Br, —OCH3, —OCF3, —CN,
—C1-6alkyl optionally substituted by up to 3 halogen, hydroxyl, or —OC1-4alkyl groups, —S(O)C1-4alkyl, —S(O)2C1-4alkyl, —C(O)N(R9)2, —C(O)N(R13)C1-4alkylOC1-4alkyl, —C(O)N(C1-4alkylOC1-4alkyl)2, —CH2C(O)N(R9)2, —CH2C(O)N(R13)C1-4alkylOC1-4alkyl, —CH2C(O)N(C1-4alkylOC1-4alkyl)2, —S(O)2NHC1-4alkyl, —S(O)2N(C1-4alkyl)2, —NHC1-4alkyl, —N(C1-4alkyl)2, —NHC(O)C1-4alkyl, —NHC(O)CF3, —NHS(O)2C1-4alkyl, CH2N(R13)2, CH2N(R13)C(O)C1-4alkyl, CH2N(R13)S(O)2C1-4alkyl, —CH2S(O)2C1-4alkyl, and CO2H;
s is 0, 1, 2, or 3;
each R2 is independently selected from the group consisting of —F, —Cl, —Br, —OCH3, —OCF3, —CN, —C1-4alkyl optionally substituted by up to 3 halogen or hydroxyl groups, —S(O)C1-4alkyl, —S(O)2C1-4alkyl, —S(O)2NHC1-4alkyl, —S(O)2N(C1-4alkyl)2, —NHC1-4alkyl, —N(C1-4alkyl)2, —NHC(O)C1-4alkyl, —NHC(O)CF3, and —NHS(O)2C1-4alkyl;
q is 0 or 1;
R3 is hydrogen or methyl; R4 is hydrogen or methyl;
R5 is hydrogen; R6 is hydrogen or C1-6alkyl optionally substituted by up to 3 —F, —Cl, —Br, —OH, —OCH3, —OCF3 or —CN groups;
when present R10 is hydrogen or methyl;
when present R11 is hydrogen or methyl;
or the R3 group and the R5 group and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and bond, or the intervening atoms and —(CHRa)r—; or the R10 group and the R5 group and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and —(CHRa)r—;
r is 1, 2, 3, 4 or 5; Ra is hydrogen or methyl;
each R7 is independently selected from the group consisting of hydrogen, halogen, C1-4alkoxy, and C1-4alkyl optionally substituted with 1, 2 or 3 halogens; and
R8 is selected from the group selected from hydrogen and C1-4alkyl;
each R9 is independently selected from the group consisting of hydrogen and C1-4alkyl, or two R9 groups and the N they are bonded to form a 4 to 7 membered non-aromatic heterocycle, the heterocycle optionally comprising 1 or 2 further heteroatoms selected from N, O and S;
each R13 is independently selected from the group consisting of hydrogen and C1-4alkyl; and wherein:
i) E, J and G are each C(R7), K is carbon, Q is N(R8), and M is nitrogen;
ii) E, J and G are each C(R7), and K, Q and M are each nitrogen; or
iii) E, J, G and M are each C(R7), and K and Q are each nitrogen,
or a salt thereof.

### Claim 95 (depends on 94)

The ADC or salt thereof according to claim 94, wherein the NMT inhibitor is a compound of formula (II):
wherein:
R1 is H or —CH3; and
R2 is H or F,
or a salt thereof.

### Claim 96 (depends on 95)

The ADC or salt thereof according to claim 95, wherein the NMT inhibitor is 4-(2-{2-[3-(2-aminoethyl)imidazo[1,2-a]pyridyl-6-yl]-5-chlorophenoxy}ethyl)-N,N,1,5-tetramethyl-1H-pyrazole-3-carboxamide:
or a salt thereof.

### Claim 97 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the NMT inhibitor is a compound of formula (III) or (IV):
wherein:
n1 is 0, 1, 2, 3, 4, 5 or 6;
Ring A*, is an optionally substituted nitrogen containing aryl group, wherein each substituted carbon or nitrogen in Ring A* is optionally and independently substituted by one or more R5A and wherein if Ring A* contains an —NH— moiety that nitrogen may be optionally substituted by C1-6alkyl; and wherein R4A and Ring A* together with the atoms to which they are attached may form a cyclic group,
Ring B* is an optionally substituted aryl or heteroaryl group wherein each substitutable carbon or heteroatom in Ring B* is optionally and independently substituted by one or more R3A;
W and X, one of which may be absent, are independently selected from R11A, hydrocarbyl optionally substituted with R11A, and —(CH2)k1-heterocyclyl optionally substituted with R12A; k1 is 0, 1, 2, 3, 4, 5 or 6;
R1A is hydrogen;
R2A, R3A, R4A and R5A are independently selected from hydrogen, R12A, hydrocarbyl optionally substituted with R12A and a —(CH2)L1—heterocyclyl optionally substituted with one or more R12A; wherein R2A taken together with W or X may form a heterocycle optionally substituted with one or more R12A; and wherein one or more of R3A and R5A taken together with the atoms to which they are attached may form a carbocycle, optionally substituted with R12A; L1 is 0, 1, 2, 3, 4, 5 or 6;
wherein:
each R11A and R12A is independently selected from halogen, trifluoromethyl, cyano, thio, nitro, oxo, ═NR13A, —OR13A, —SR13A, —C(O)R13A, —C(O)OR13A, —OC(O)R13A, —NR13ACOR14A, —NR13ACON(R13A)2, —NR13aCOR14a, —NR13aCO2R14A, —S(O)R13A, —S(O)2R13A, —SON(R13A)2, —NR13AS(O)2R14A; —CSR13A, —N(R13A)R14A, —C(O)N(R13A)R14A, —SO2N(R13A)R14A and R15A;
R13A and R14A are each independently selected from hydrogen or R15A;
R15A is selected from hydrocarbyl, carbocyclyl and —(CH2)m1-heterocyclyl, and each R15A is optionally and independently substituted with one or more of halogen, cyano, amino, hydroxy, C1-6alkyl or cycloalkyl and C1-6alkoxy;
m1 is 0, 1, 2, 3, 4, 5 or 6;
p1 is 0, 1, 2, 3 or 4; the values of R4A may be the same or different; and
q1 is 0, 1, 2, 3 or 4; wherein the values of R5A may be the same or different;
Y and Z, one or both of which may be absent, are independently selected from hydrogen, R16A, hydrocarbyl optionally substituted with R16A, and —(CH2)r1-heterocyclyl optionally substituted with R16A, wherein each R16A is independently selected from halogen, trifluoromethyl, cyano, thio, nitro, oxo, ═NR17A, —OR17A, —SR17A, —C(O)R17A, —C(O)OR17A, —OC(O)R17A, —NR17ACOR18A, —NR17ACON(R18A)2, —NR17ACOR18A, —NR17ACO2R18A, —S(O)R17A, —S(O)2R17A,
SON(R17A)2, —NR17AS(O)2R18A; —CSR17A, —N(R17A)R18A, —C(O)N(R17A)R18A, —SO2N(R17A)R18A and R19A; r1 is 0, 1, 2, 3, 4, 5 or 6;
wherein:
R17A and R18A are each independently selected from hydrogen or R19A;
R19A is selected from hydrocarbyl, carbocyclyl and —(CH2)s1-heterocyclyl, and each R19A is optionally and independently substituted with one or more of halogen, cyano, amino, hydroxy, C1-6alkyl and C1-6alkoxy; and
s1 is 0, 1, 2, 3, 4, 5 or 6,
or a salt thereof.

### Claim 98 (depends on 97)

The ADC or salt thereof according to claim 97, wherein the NMT inhibitor is (2,6-dichloro-4-(2-piperazin-1-yl-pyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyraxol-4-yl)-benzenesulfonamide):
or a salt thereof; or wherein the NMT inhibitor is 2,6-dichloro-N-(5-isobutyl-1,3-dimethyl-1H-pyrazol-4-yl(-4-(2-piperazin-1-yl-pyridin-4-yl)-benzenesulfonamide:
or a salt thereof.

### Claim 99 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the NMT inhibitor is a compound of formula (V):
wherein:
n1 is 1 or 2; n2 is 1 or 2;
X1 is selected from the group consisting of CRx and N;
when present, Rx is selected from the group consisting of hydrogen, halogen, and —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3;
R1 is selected from the group consisting of hydrogen; —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OCH3, and —OCF3; and —C3-6cycloalkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —CH3, —OCH3, and —OCF3;
R2 is selected from the group consisting of hydrogen; —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OCH3, and —OCF3; and —C3-6cycloalkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —CH3, —OCH3, and —OCF3;
or R1 and R2 are linked such that together with the atom to which they are attached they form a C3-6cycloalkyl group or a 3- to 6-membered non-aromatic heterocyclyl group comprising 1 heteroatom selected from the group consisting of O and N, wherein said C3-6cycloalkyl group or 3- to 6-membered non-aromatic heterocyclyl group is optionally substituted by 1 or 2 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —CH3, —OCH3, and —OCF3;
R3 is selected from the group consisting of hydrogen; —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3; and —C3-6-cycloalkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —CH3, —OCH3, and —OCF3;
or R1 and R3 are linked such that together with the atoms to which they are attached they form a 3- to 6-membered non-aromatic heterocyclyl group comprising 1 N heteroatom, wherein said 3- to 6-membered non-aromatic heterocyclyl group is optionally substituted by 1 or 2 substituents, each substituent being independently selected from the group consisting of halogen, —CH3, —OH, —OCH3, and —OCF3;
X2 is selected from the group consisting of CR4 and N;
when present, R4 is selected from the group consisting of hydrogen; halogen; —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, —OCF3, and —NRaRb;
R5a and R5d are independently selected from the group consisting of hydrogen; halogen; methyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3; and methoxy optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3;
R5b and R5c are independently selected from the group consisting of hydrogen; halogen; —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3; —O—C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3; and C3-6cycloalkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —CH3, —OH, —OCH3, and —OCF3;
or R5b and R5c are linked such that together with the atoms to which they are attached they form a 6-membered aryl group or a 5- or 6-membered aromatic heterocyclyl group comprising 1 or 2 heteroatoms selected from the group consisting of S, O and N, wherein said 6-membered aryl group or 5- or 6-membered aromatic heterocyclyl group is optionally substituted by 1 or 2 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3;
R6 is selected from the group consisting of hydrogen and methyl;
when present, each R7 is —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3;
R8 is selected from the group consisting of hydrogen; halogen; —OH; —CN; —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —CN, and methoxy optionally substituted by 1, 2 or 3 halogen; —C3-6cycloalkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —CH3, —OH, —CN, and methoxy optionally substituted by 1, 2 or 3 halogen; —C1-4alkenyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —CN, and methoxy optionally substituted by 1, 2 or 3 halogen; and —O—C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, CN and methoxy optionally substituted by 1, 2 or 3 halogen;
R9 is selected from the group consisting of hydrogen, and —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, —OCH3, and —OCF3; or
R8 and R9 are linked such that together with the atoms to which they are attached they form a 6-membered aryl group, a C5-6cycloalkyl group, or a 5- or 6-membered aromatic heterocyclyl group comprising 1 or 2 heteroatoms selected from N, O and S, and wherein said 6-membered aryl group, C5-6cycloalkyl group or 5- to 6-membered aromatic heterocyclyl group is optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen; —OH; —CN; —C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and methoxy optionally substituted by 1, 2 or 3 halogen; and —O—C1-4alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of -halogen, —OH, and methoxy optionally substituted by 1, 2 or 3 halogen;
p is 0, 1, or 2;
Z is a 5- to 13-membered non-aromatic heterocyclyl group comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein at least one of the heteroatoms is N, and wherein said 5- to 13-membered non-aromatic heterocyclyl group is optionally substituted with 1, 2, 3 or 4 substituents, each substituent being independently selected from the group consisting of halogen; —C1-6alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and —OC1-3alkyl optionally substituted by 1, 2 or 3 halogen; —O—C1-6alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and —O—C1-3alkyl optionally substituted by 1, 2 or 3 halogen;
NRcRd; and C3-6cycloalkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and —O—C1-3alkyl optionally substituted by 1, 2 or 3 halogen; or
when two substituents are on adjacent ring positions they may be linked such that together with the atoms to which they are attached they form a C3-6cycloalkyl group or a 4- to 6-membered non-aromatic heterocyclyl group comprising 1 heteroatom selected from the group consisting of 0 and N, wherein said C3-6cycloalkyl group or 4- to 6-membered non-aromatic heterocyclyl group is optionally substituted by 1 or 2 substituents, each substituent being independently selected from the group consisting of halogen; —C1-6alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and —OC1-3alkyl optionally substituted by 1, 2 or 3 halogen; and —O—C1-6alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and —O—C1-3alkyl optionally substituted by 1, 2 or 3 halogen;
Rc is hydrogen;
Rd is selected from the group consisting of hydrogen; —C1-6alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OCH3, and —OCF3; and C3-6cycloalkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —CH3, —OH, —OCH3, and —OCF3;
or Z is —NR10R11, wherein
R10 is hydrogen; and
R11 is a 5- to 10-membered non-aromatic heterocyclyl group comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein at least one of the heteroatoms is N, and wherein said 5- to 10-membered non-aromatic heterocyclyl group is optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of halogen; —OH; —C1-6alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and —OC1-3alkyl optionally substituted by 1, 2 or 3 halogen; and —O—C1-6alkyl optionally substituted by 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of halogen, —OH, and —O—C1-3alkyl optionally substituted by 1, 2 or 3 halogen; and
when present, each Ra and Rb are independently selected from the group consisting of hydrogen and —C1-4alkyl, or a salt thereof.

### Claim 100 (depends on 99)

The ADC or salt thereof according to claim 99, wherein the NMT inhibitor is (S)-1-(5-chloro-2-(2-methylpiperazin-1-yl)pyrimidin-4-yl)-N-(2-(imidazo[1,2-a]pyridine-3-yl)propan-2-yl)azetidine-3-carboxamide:
or a salt thereof.

### Claim 101 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the NMT inhibitor is a compound of formula (VI):
wherein:
R1 is a group of formula O-L-A;
L is —(CHR12)m—;
each R12 is independently H or C1-4alkyl;
m is 1, 2 or 3;
A is:
v is 0, 1 or 2;
R9a is H, C1-4alkyl or C1-4haloalkyl;
R9b is H, C1-4alkyl or C1-4haloalkyl;
R9c is C1-4alkyl or C1-4haloalkyl;
R9d is H, C1-4alkyl or C1-4haloalkyl;
R10 is H, C1-4alkyl or C1-4haloalkyl;
R11 is H, halo, CN, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy or C1-4haloalkoxy;
s is 0, 1, 2 or 3;
each R2 is independently F, Cl, Br, C1-4alkyl optionally substituted by up to 3 halogen groups, OCH3 or OCF3;
Y is CH or C1-4alkyl;
R3 is H or C1-4alkyl;
R4 is H or C1-4alkyl;
R5 is H;
R6 is H or C1-4alkyl;
q is 0 or 1;
R7 is H or methyl;
R8 is H or methyl;
or R3 and R6 and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and bond, or the intervening atoms and —(CHRa)r—; or the R7 group and the R6 group and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and —(CHRa)r—;
r is 1, 2, 3, 4 or 5; and
Ra is hydrogen or methyl,
or a salt thereof.

### Claim 102 (depends on 101)

The ADC or salt thereof according to claim 101, wherein the NMT inhibitor is 1-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}-2,2-dimethylpropan-1-ol:
or a salt thereof.

### Claim 103 (depends on 101)

The ADC or salt thereof according to claim 101, which is 2-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}propan-2-ol:
or a salt thereof.

### Claim 104 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the linker has the following formula (VII):
wherein:
A is a first stretcher unit which when present forms a covalent bond with a chain terminus or a functional group of an amino acid side chain of the antibody;
a is 0 or 1;
each W is independently an amino acid unit or a glucuronide unit which when A and/or Y are absent forms a covalent bond with a chain terminus or a functional group of an amino acid side chain of the antibody and/or with a functional group of the NMT inhibitor respectively;
when W is an amino acid, w is 1 to 12;
when W is a glucuronide unit, w is 1 or 2;
Y is a second stretcher unit which when present forms a covalent bond with a functional group of the NMT inhibitor; and
y is 0 or 1, or a salt thereof.

### Claim 105 (depends on 104)

The ADC or salt thereof according to claim 104, wherein the linker has the formula (LI):
wherein denotes the point of attachment to a chain terminus or a functional group on an amino acid side chain of the antibody; and
denotes the point of attachment to a functional group of the NMT inhibitor; or
wherein the linker has the formula (LII):
wherein denotes the point of attachment to a chain terminus or a functional group on an amino acid side chain of the antibody; and
denotes the point of attachment to a functional group of the NMT inhibitor; or
wherein the linker has the formula (LIII):
wherein denotes the point of attachment to a chain terminus or a functional group on an amino acid side chain of the antibody; and
denotes the point of attachment to a functional group of the NMT inhibitor; or
wherein the linker has the formula (LIV):
wherein denotes the point of attachment to a chain terminus or a functional group on an amino acid side chain of the antibody; and
denotes the point of attachment to a functional group of the NMT inhibitor, or a salt thereof.

### Claim 106 (depends on 104)

The ADC or salt thereof according to claim 104, wherein the functional group on the NMT inhibitor is an amino.

### Claim 107 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the antibody binds to HER2.

### Claim 108 (depends on 107)

The ADC or salt thereof according to claim 107, wherein the antibody is trastuzumab, pertuzumab, margetuximab, ertumaxomab, MM-111, MCLA-128, ZW25, MDX-210, ado-trastuzumab or fam-trastuzumab.

### Claim 109 (depends on 108)

The ADC or salt thereof according to claim 108, wherein the antibody is trastuzumab.

### Claim 110 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the antibody binds to CD20.

### Claim 111 (depends on 110)

The ADC or salt thereof according to claim 110, wherein the antibody is rituximab.

### Claim 112 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the antibody binds to Trop-2.

### Claim 113 (depends on 112)

The ADC or salt thereof according to claim 112, wherein the antibody is sacituzumab.

### Claim 114 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the antibody binds to B7-H3.

### Claim 115 (depends on 114)

The ADC or salt thereof according to claim 114, wherein the antibody is ifinatamab.

### Claim 116 (depends on 93)

The ADC or salt thereof according to claim 93, wherein the drug loading (p) of NMT inhibitor to antibody is between 1 to 10 NMT inhibitor(s) to antibody.

### Claim 117 (depends on 93)

A pharmaceutical composition comprising the ADC according to claim 93, and a pharmaceutically acceptable salt thereof.

### Claim 118 (depends on 93)

A method of preventing or treating a disease or disorder in a subject in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, said method comprising administering a therapeutically effective amount of an ADC according to claim 93, or a pharmaceutically acceptable salt thereof.

### Claim 119 (depends on 118)

The method according to claim 118, wherein the disease or disorder is a hyperproliferative disorder, and wherein the hyperproliferative disorder is cancer.

### Claim 120 (depends on 119)

The method according to claim 119, wherein the cancer is breast cancer, bladder cancer, lung cancer, prostate cancer, kidney cancer, esophageal carcinoma, colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma, leukemia or neuroblastoma.

### Claim 121 (depends on 119)

The method according to claim 119, wherein the cancer is a haematologic malignancy or a solid-tumor.

### Claim 122

A drug conjugate or salt and/or solvate thereof comprising a NMT inhibitor and a linker, wherein the linker comprises a group capable of forming a covalent bond to a chain terminus or a functional group on an amino acid side chain of an antibody.

### Claim 123 (depends on 122)

The drug conjugate according to claim 122, wherein the drug conjugate has the formula (DC-2):
or a salt and/or solvate thereof, wherein NMT is the NMT inhibitor.

### Claim 124 (depends on 123)

The drug conjugate according to claim 123, which is (1S,2R,3S,4R,5R)-5-(4-{[({[6-(3,4-difluoro-2-{2-[3-(1-hydroxy-2,2-dimethylpropyl)-1,5-dimethyl-1H-pyrazol-4-yl]ethoxy}phenyl)imidazo[1,2-a]pyridin-3yl]methyl}(methyl)carbamoyl)oxy]methyl}-2-[3-(3-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}propanamido)propanamido]phenoxy)-3,4-dihydroxy-2-methylcyclohexane-1-carboxylic acid:
or a salt and/or solvate thereof.

### Claim 125 (depends on 122)

The drug conjugate according to claim 122, wherein the drug conjugate has the formula (DC-1):
or a salt and/or solvate thereof, wherein NMT is the NMT inhibitor.

### Claim 126 (depends on 125)

The drug conjugate according to claim 125, which is {4-[(2S)-5-(carbamoylamino)-2-[(2S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido]pentanamido]phenyl}methyl N-{[6-(3,4-difluoro-2-{2-[3-(1-hydroxy-2,2-dimethylpropyl)-1,5-dimethyl-1H-pyrazol-4-yl]ethoxy}phenyl)imidazo[1,2-a]pyridin-3-yl]methyl}-N-methylcarbamate:
or a salt and/or solvate thereof.

### Claim 127

A compound selected from the group consisting of:
a compound of formula (ADC-I):
and
a compound of formula (ADC-II):
wherein NMT is the NMT inhibitor, or a salt and/or solvate of any one thereof.

### Claim 128 (depends on 102)

The ADC according to claim 102, wherein the NMT inhibitor is 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol or a salt and/or solvate thereof, wherein the compound is the isomer having the stereochemical arrangement of:
or a salt thereof.

### Claim 129 (depends on 102)

The ADC according to claim 102, wherein the NMT inhibitor is 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol or a salt and/or solvate thereof, wherein the compound is the isomer having the stereochemical arrangement of:
or a salt thereof.

### Claim 130 (depends on 107)

The ADC or salt thereof according to claim 107, wherein the antibody has the CDRs of the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 131 (depends on 116)

The ADC or salt thereof according to claim 116, wherein the drug loading (p) of NMT inhibitor to antibody is between 4 to 6 NMT inhibitors to antibody.

### Claim 132 (depends on 93)

The ADC according to claim 93, wherein the ADC comprises the following formula:
or a salt thereof, wherein Ab is an antibody,
represents the NMT inhibitor or a salt thereof, and p is the drug loading of NMT inhibitor to antibody, and is between 1 to 10 NMT inhibitor(s) to antibody.

### Claim 133 (depends on 132)

The ADC according to claim 132, wherein the ADC comprises the following formula:
or a salt thereof, wherein Ab is an antibody, and p is the drug loading of NMT inhibitor to antibody, and is between 1 to 10 NMT inhibitor(s) to antibody.

### Claim 134 (depends on 93)

The ADC according to claim 93, wherein the ADC comprises the following formula:
or a salt thereof, wherein Ab is an antibody,
represents the NMT inhibitor or a salt thereof, and p is the drug loading of NMT inhibitor to antibody, and is between 1 to 10 NMT inhibitor(s) to antibody.

### Claim 135 (depends on 134)

The ADC according to claim 134, wherein the ADC comprises the following formula:
or a salt thereof, wherein Ab is an antibody, and p is the drug loading of NMT inhibitor to antibody, and is between 1 to 10 NMT inhibitor(s) to antibody.

### Claim 136 (depends on 132)

The ADC or salt thereof according to claim 132, wherein the antibody of the ADC is bound via a sulfhydryl group on the side chain of an amino acid on the antibody.

### Claim 137 (depends on 134)

The ADC or salt thereof according to claim 134, wherein the antibody of the ADC is bound via a sulfhydryl group on the side chain of an amino acid on the antibody.
